Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
4th Military Clinical Hospital with Polyclinic, Wrocław, Dolnośląskie, Poland
SNUCH, Seoul, Korea, Republic of
University Hospital Split, Split, Croatia
Children's Health Dallas, Dallas, Texas, United States
Institut Jantung Negara, Kuala Lumpur, Malaysia
the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
University Hospital, Columbia, Missouri, United States
Chosun University Hospital, Gwangju, Korea, Republic of
Ain Shams University Hospitals, Cairo, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.